Analysis of medical malpractice litigation following vertebral augmentation therapy in China from 2008 to 2018

Dong Hu, MD\textsuperscript{a,b}, Huawei Liu, MD\textsuperscript{a}, Bei Yuan, MD\textsuperscript{a}, Suxi Gu, MD\textsuperscript{a}, Kai Xu, MD\textsuperscript{a}, Fei Song, MD\textsuperscript{a}, Songhua Xiao, MD\textsuperscript{a,b,*}

\textsuperscript{a} Department of Orthopaedics, Beijing Tsinghua Changgung Hospital, School of Clinical Medicine, Tsinghua University, Beijing, P.R. China, \textsuperscript{b} Institute for Precision Medicine, Tsinghua University, Beijing, P.R. China.

The authors have no conflicts of interest to disclose.

The datasets generated during and/or analyzed during the current study are publicly available.

This study was supported by Tsinghua Precision Medicine Foundation.

The first case of vertebral augmentation therapy in mainland China was reported in 2000. Since then, it has been widely used in China as a minimally invasive procedure to treat vertebral compression fractures. However, the characteristics of malpractice litigation involving vertebral augmentation therapy remains unclear. This study aims to analyze the characteristics of medical malpractice litigation involving vertebral augmentation therapy in mainland China for the past 10 years. Two online legal databases were queried for court verdicts involving vertebral augmentation therapy from Jan 2009 to Dec 2018 in mainland China. Each case file was then thoroughly reviewed and data pertaining to defendants, plaintiffs, case outcomes, allegations, and verdicts were abstracted, and descriptive analyses were performed. Level of evidence: LEVEL III. A total of 96 cases were enrolled for final analysis. The number of claims increased by five times during the past 10 years. More than two thirds (67.7\%, n = 65) of the cases underwent percutaneous vertebroplasty, and 22.9\% (n = 22) underwent percutaneous kyphoplasty, the rest (8.4\%, n = 9) remained undefined. Paralysis was alleged in 35.4\% of cases (n = 34), followed by significant physical injury (34.4\%, n = 33). Cement leakage to spinal canal (44.8\%, n = 43) is the most commonly cited reason for litigation, followed by incomplete informed consent (42.7\%, n = 41), accidental dural puncture (20.8\%, n = 20), unsatisfactory clinical outcome (18.8\%, n = 18), and misdiagnosis (12.5\%, n = 12). Acute pulmonary cement embolism (4.2\%, n = 4), wrong-level vertebrae procedure (3.1\%, n = 3) and postoperative infection (2.1\%, n = 2) were less common causes for concern. Doctors successfully defended themselves only in 8 (8.3\%) cases, which resulted in no indemnity payment. The rest 88 (91.7\%) cases were closed with a mean verdict payout of 361,580 Yuan (51,654 US dollars). There is a quickly rising trend in the number of medical malpractice litigation involving vertebral augmentation therapy in China. Identifying the most common reasons for litigation and summarizing their characteristics may help decrease litigation rate and improve the patient experience.

Abbreviations: PKP = percutaneous kyphoplasty, PVP = percutaneous vertebroplasty.

Keywords: China, litigation, malpractice, PKP, PVP, vertebral augmentation therapy

1. Introduction

Medical malpractice lawsuits pose economic and emotional burdens that weigh heavily on both the physician and the patient. Recent trends showing incidence of medical malpractice litigation in China is increasing rapidly.\cite{1}

Vertebral augmentation therapy emerged in the 1990s as a surgical approach to reduce pain and deformity after a vertebral fracture.\cite{13} As currently practiced, vertebral augmentation therapy includes either percutaneous vertebroplasty (PVP), where bone cement is injected percutaneously into the vertebral body, or balloon kyphoplasty (PKP), where a balloon or bone tamp is introduced into the vertebral body, inflated, and then injected with bone cement. The first reported case of vertebral augmentation therapy in mainland China was published in 2000.\cite{3} Despite of the controversial benefits of vertebral augmentation therapy, this technique became popular among mainland China during the past 2 decades.\cite{14}

Prior studies have explored medical malpractice litigation related to spine surgery in different countries.\cite{15-17} However, no previous study investigated the malpractice litigation specifically focused on vertebral augmentation therapy. Identifying the most common reasons for litigation and summarizing their characteristics may help decrease litigation rate and improve the patient experience. This study aimed to examine trends and patterns of vertebral augmentation therapy related litigation in mainland China from 2008 to 2018. Medicine 2022;101:41(e30972). How to cite this article: Hu D, Liu H, Yuan B, Gu S, Xu K, Song F, Xiao S. Analysis of medical malpractice litigation following vertebral augmentation therapy in China from 2008 to 2018. Medicine 2022;101:41(e30972).

Received: 15 March 2022 / Received in final form: 2 September 2022 / Accepted: 6 September 2022

http://dx.doi.org/10.1097/MD.0000000000030972
China during the past 10 years, using the Wusong and Weike legal databases.

2. Methods

Publicly available court verdicts related to vertebral augmentation therapy malpractice litigation in mainland China, from January 2009 to December 2018, were identified in two online legal databases (Westlaw and Weike). These databases provide online legal research service for lawyers and legal professionals which can provide information regarding national cases in China. Court verdicts were obtained using the search terms “vertebroplasty”, “kyphoplasty”, “PVP”, “PKP” and “malpractice”. Exclusion criteria included duplicate cases, unrelated topics, and lack of reported data. Each case file was then thoroughly reviewed and data pertaining to defendants, plaintiffs, case outcomes, allegations, and verdicts were abstracted, and descriptive analyses were performed. Severity of damage was graded from minor/temporary to death. Data analysis was carried out using Excel and Graphpad, and statistical significance was calculated using a two-tailed Student’s t test. Ethical approval for this study was waived by Ethics Committee of Tsinghua Changgung Hospital because this study was conducted on public available data.

3. Results

In total, 148 cases were identified from the two databases initially; Thirty-one cases were repeated and 21 cases were excluded for missing information or irrelevance, leaving a total of 96 cases for final analysis (Fig. 1). The number of claims increased by five times during the past 10 years. The year in which claims were judged is displayed in Figure 2.

The mean age of the plaintiffs was 68.6 ± 10.3 years. Thirty cases (31.2%) of the plaintiffs were male and 66 cases (68.8%) were female. Among all the included medical malpractice cases, 72 cases (75.0%) occurred in public hospitals while 24 cases (25.0%) occurred in private ones. It should be noted that the vast majority of medical dispute cases happened in public hospitals were concentrated in tertiary hospitals (70.8%, n = 51).

As shown in Table 1, the most common primary disease leading to treatment is osteoporotic fracture (83.3%, n = 80), followed by trauma (9.4%, n = 9), spinal tuberculosis (5.2%, n = 5), and spinal metastasis tumor (2.1%, n = 2). These pathologic vertebrae located most commonly in the thoracolumbar vertebrae (87.5%, n = 84), followed by midthoracic vertebrae (8.3%, n = 8) and lower lumbar vertebrae (4.2%, n = 4). Sixty-eight cases (70.8%) involved single vertebrae during their augmentation therapy, 24 cases (25.0%) involved two vertebrae, and 4 cases (4.2%) involved three or even more vertebrae. More than two thirds (67.7%, n = 65) of the cases underwent PVP, 22.9% (n = 22) underwent PKP, and the rest (9.4%, n = 9) remained undefined.

We further analyzed the disability determination report of patients. Paralysis was alleged in the in the vast majority of cases (35.4%, n = 34), followed by significant physical injury (34.4%, n = 33). Minor or temporary alleged injuries were less common (25.0%, n = 24). Patient death was noted in 5 cases (5.2%).

To glean a better understanding of the motivating force behind each claim, an attempt was made to isolate the main issues from the patient’s perspective. As shown in Figure 3, cement leakage to spinal canal (44.8%, n = 43) is the most commonly cited reason for litigation, followed by incomplete informed consent (42.7%, n = 41), accidental dural puncture (20.8%, n = 20), unsatisfactory clinical outcome (18.8%, n = 18), and misdiagnosis (12.5%, n = 12). Acute pulmonary cement embolism (4.2%, n = 4), wrong-level vertebrae procedure (3.1%, n = 3) and postoperative infection (2.1%, n = 2) were less common causes for concern.

A total of 42 cases (43.8%) received additional surgery, among which 36 cases underwent surgical exploration and decompression, 4 cases underwent posterior long segment internal fixation, and 2 cases underwent debridement. Among the 12 cases with the claim of misdiagnosis, there were 6 cases of missing fresh fractured vertebrae, 4 cases of delayed diagnosis of spinal tuberculosis, and 2 cases of delayed diagnosis of spinal metastasis tumor.

The most likely outcome of included litigation was a jury verdict in favor of the plaintiff, as shown in Table 2. Doctors successfully defended themselves only in 8 (8.3%) cases, which resulted in no indemnity payment. The rest 88 (91.7%) cases were closed with a mean verdict payout of 361,580 Yuan (range 15,614–3564,120 Yuan), which was significantly lower than the mean compensation claimed by the plaintiff (921819 Yuan, range 91,023–7248,070 Yuan) (P < .05). On average, it took 26.19 months (range 6–90 months) after the date of first operation for the case to end via verdict. Among the cases that surgeons were held not guilty, the time elapsed from the first surgery to
Table 1
Case characteristics and medical details.

| Variable                        | Value |
|---------------------------------|-------|
| Sex (male %)                    | 30 (31.2%) |
| Age                             | 68.6 ± 10.3 |
| Hospital involved (%)           | Public 72 (75.0%), Private 24 (25.0%) |
| Primary diseases                | Osteoporotic fracture 80 (83.3%), Trauma 9 (9.4%), Spinal tuberculosis 5 (5.2%), Spinal metastasis tumor 2 (2.1%) |
| Procedure location              | Midthoracic vertebrae (T5–T8) 8 (8.3%), Thoracolumbar vertebrae (T11–L2) 84 (87.5%), Lower lumbar vertebrae (L3–L5) 4 (4.2%) |
| Number of vertebrae involved    | 1 68 (70.8%), 2 24 (25.0%), >2 4 (4.2%) |
| Operation type                  | PVP 65 (67.7%), PKP 22 (22.9%), Unidentified 9 (9.4%) |
| Damage severity (%)             | Minor, Temporary 24 (25.0%), Significant Physical 33 (34.4%), Paralysis 34 (35.4%), Death 5 (5.2%) |

PKP = percutaneous kyphoplasty, PVP = percutaneous vertebroplasty.

Figure 3. Number of cases for each reason that led to a malpractice claim following vertebral augmentation therapy.

The present study observed that three-quarter of the enrolled medical litigation cases occurred in public hospitals rather than in private ones. This may be explained by the fact that healthcare services provided by the private sector were far less compared with that from public hospitals in China before 2009, when national reform of health care promoted universal health coverage. We also observed that the vast majority of medical dispute cases were concentrated in tertiary hospitals rather than in lower-level medical settings. A similar striking finding was found in a study by He et al, where tertiary hospitals constituted as high as 59.5% of all medical malpractice cases.[9] The current medical system in China might explain the remarkable number of medical disputes in upper-level healthcare facilities, as China has not yet established a mature dividing system for patients. Patients more likely influx into upper-level healthcare facilities without necessary relation to their disease severity.

Another interesting finding was that more than two thirds of cases in current study involved PVP, much higher than the proportion of PKP involved litigation cases ($P < .05$). This phenomenon may be explained by multiple reasons. First, lots of studies demonstrated that PKP is superior to PVP for its lower cement leakage rate.[10–12] Second, the time when PKP technique entering the China market was later than that of PVP. Third, PKP is less pervasive compared with PVP in China because of its higher material cost and longer operation time.[4]

Although vertebral augmentation therapy is a minimally invasive procedure, it is not free of complications and side effects.[11–16] Among all the iatrogenic reasons in our study, cement leakage to spinal canal accounts for the most frequent complaint. Previous studies demonstrated that the incidence of cement leakage vary from less than 3% to more than 80% of all performed vertebral augmentation procedures.[17–20] Although most leakage was clinically asymptomatic, serious complications occurred in 3.9% to 7.5% of the patients.[14] Combined with the high percentage of cases complained with incomplete informed consent in our study, we suggested that informed consent should involve discussion of all potential risks, especially the risk of cement leakage, during the procedure. Sound and clear communication and complete documentation can help reducing the risk of litigation and protect the doctors if perceived negligence occurs.

On the other hand, nearly 20% of cases complained with unsatisfactory outcome for back pain control. It was believed that bone cement injected into the fractured vertebra during this type of procedure fused the fragments of the vertebra together, and thereby reducing bone pain. However, sometimes patient’s back pain have multiple origins, such as spinal process, fractured vertebra or soft tissue.[13,21] Hence, we suggest that VPP/ PKP intervention should be carried out until local back pain persists after 3 weeks of conservative treatment according to the international literatures.[22–24] What’s more, a discussion of the possible residual pain should be noticed in the informed consent to avoid an irrational expectation.

Surprisingly, only 8.3% claims were closed in favor of the defendant doctors in current study, which is extreme low. It seems that doctors in China are more likely to lose the lawsuit compared with their western country counterparts. This may be explained by the differences in providing evidences among medical malpractice litigation in Chinese legal systems. For a patient/plaintiff to win a medical malpractice litigation suit in western countries, he/she must demonstrate that a physician was negligent. However things are far different in China since 2002 when the People’s Supreme Court issued a regulation to invert the evidential burden in medical malpractice litigation, aimed improving the situation of information asymmetry between patient and physician. In other words, the defendant doctor needs to demonstrate him/herself not guilty by providing full and complete documentation in medical malpractice litigation in China.

Figure 3. Number of cases for each reason that led to a malpractice claim following vertebral augmentation therapy.

the end of verdict was 43 months (range 15–83 months), which is significant lengthier than 24.66 months (range 6–90 months) of guilty ($P < .05$).

4. Discussion

Medical malpractice is a huge problem around the world. The present study was the first one to analyze vertebral augmentation therapy related malpractice claims. A significant year-based increase in the incidence rate of malpractice litigation was observed in current study, which is consistent with the increasing cases of medical malpractice litigation among previous studies from China.[1,8]
Malpractice litigation is costly from a financial perspective, and its monetary burden on healthcare systems worldwide keeps rising. For the entire included cases in current study, the average verdict payout (331,448 Yuan, around 47,350 US dollars) is significant lower than the average plaintiff claimed payout (861,884 Yuan, around 123,126 US dollars) (P < .05). This number is significantly lower than the average compensation claim for litigation and summarizing their characteristics may help us to understand the distribution of incidence in China. Finally, the information presented in these cases is primarily legal in nature and medical details from most cases are not publicly reported, which limits the available information on claims. In conclusion, there is a quickly rising trend in the number of medical malpractice litigation involving vertebral augmentation therapy in China. Claims were closed in favor of the plaintiff (84.4% vs 81.5%). Showing that doctors in China are at a disadvantage and it would be a long-running twist of bitterness for them to win a lawsuit involving vertebral augmentation therapy.

We are fully aware of possible limitations. First of all, although court records are available via legal databases, reporting of cases is not mandatory and is at the discretion of individual court systems and judges. The cases captured may not represent all of the cases in China and may not represent the true distribution of the different reasons for lawsuits and decisions. Secondly, the databases contain only cases with a court verdict and do not include cases that were dropped/dismissed at an earlier stage. Out-of-court settlements may not have been filed under court records. Given that a majority of claims do not end into trial, it is unsurprising that our analysis may only captured a fraction of the total number of claims in China. Finally, the information presented in these cases is primarily legal in nature and medical details from most cases are not publicly reported, which limits the available information on claims.

In conclusion, there is a quickly rising trend in the number of medical malpractice litigation involving vertebral augmentation therapy in China. Claims were closed in favor of the plaintiff in the majority of cases. Identifying the most common reasons for litigation and summarizing their characteristics may help decrease litigation rate and improve the patient experience.

Acknowledgments
We appreciate Shiqi Dong from King & Wood Mallesons for her kindness of legal advises.

Author contributions

Conceptualization: Songhua Xiao.
Data curation: Dong Hu, Huawei Liu, Bei Yuan, Kai Xu.
Formal analysis: Dong Hu.
Investigation: Fei Song.
Methodology: Dong Hu.
Supervision: Fei Song, Songhua Xiao.
Writing – original draft: Dong Hu.
Writing – review & editing: Huawei Liu, Suxi Gu, Songhua Xiao.

References
[1] Wang Z, Li N, Jiang M, et al. Records of medical malpractice litigation: a potential indicator of health-care quality in China. Bull World Health Organ. 2017;95:430–6.
[2] Martin JB, Jean B, Sugis K, et al. Vertebroplasty: clinical experience and follow-up results. Bone. 1999;25:115–15S.
[3] Lu J. Imageologic and clinical study of percutaneous vertebroplasty. Master degree thesis. Medical imaging department: the fourth military medical university (Chinese), 2000.
[4] Yang H, Liu H, Wang S, et al. Review of percutaneous kyphoplasty in China. Spine 2016;41 Suppl 19;B52–5.
[5] Ahmadi SA, Sadat H, Scheuller KM, et al. Malpractice claims in spine surgery in Germany: a 5-year analysis. Spine J 2019;19:1221–31.
[6] Machin JT, Hardman J, Harrison W, et al. Can spinal surgery in England be saved from litigation: a review of 978 clinical negligence claims against the NHS. Eur Spine J 2018;27:2693–9.
[7] Fox MJ, Ruttinan R, Elftorzi AEM, et al. Malpractice litigation following spine surgery. J Neurosurg. 2017;27:470–5.
[8] Li H, Wu X, Sun T, et al. Claims, liabilities, injuries and compensation payments of medical malpractice litigation cases in China from 1998 to 2011. BMC Health Serv Res. 2014;14:390.
[9] He F, Li L, Bynum J, et al. Medical malpractice in Wuhan, China: a 10-year autopsy-based single-center study. Medicine (Baltimore). 2013;94:e2026.
[10] Chang X, Lv YF, Chen B, et al. Vertebroplasty versus kyphoplasty in osteoporotic vertebral compression fracture: a meta-analysis of prospective comparative studies. Int Ortho. 2015;39:491–500.
[11] Marlin F, Natthoo N, Mende E. Use of percutaneous kyphoplasty and vertebroplasty in spinal surgery, J Neurosurg Sci. 2012;56:105–12.
[12] Yan D, Duan L, Li J, et al. Comparative study of percutaneous vertebroplasty and kyphoplasty in the treatment of osteoporotic vertebral compression fractures. Arch Ortho Trauma Surg. 2011;131:645–50.
[13] Rodrigues DM, Cunha Machado DP, Campainha Fernandes SA, et al. Pulmonary cement embolism following balloon kyphoplasty: the impact of a procedural complication in a new era for lung cancer management. Mol Clin Oncol. 2019;10:299–303.
[14] Yaltirik K, Ashour AM, Reis CR, et al. Vertebral augmentation by kyphoplasty and vertebroplasty: 8 years experience outcomes and complications. J Craniofac Surg. 2016;7:153–60.
[15] Bergmann M, Oberkircher L, Blemel C, et al. Early clinical outcome and complications related to balloon kyphoplasty. Ortho Rev. 2012;4:25.
[16] Lee MJ, Dumonski M, Cahill P, et al. Percutaneous treatment of vertebral compression fractures: a meta-analysis of published evidence. World Neurosurg. 2017;101:633–42.
[17] Chen W, Xie W, Xiao Z, et al. Incidence of cement leakage between unilateral and bilateral percutaneous vertebral augmentation for osteoporotic vertebral compression fractures: a meta-analysis of randomized controlled trials. World Neurosurg 2019;122:342–8.
[18] Meng R, Qian M, Xia SX, et al. Biomechanical characteristics of cement/gelatin mixture for prevention of cement leakage in vertebral augmentation. Eur Spine J. 2013;22:2249–55.
[19] Huan Z, Shi Q, Zhu-Yong S, et al. Vertebral augmentation of osteoporotic and malignant compression fractures: our viewpoint and experience in preventing cement leakage. Pain Phys. 2012;15:ES33–5; author reply E3.
[21] Yan Y, Xu R, Zou T. Is thoracolumbar fascia injury the cause of residual back pain after percutaneous vertebroplasty? A prospective cohort study. Osteoporosis Int. 2015;26:1119–24.

[22] Yang JS, Hao DJ, Zhao YT, et al. Residual back pain after vertebroplasty. Pain Phys. 2014;17:E800–2.

[23] Luthman S, Widen J, Borgstrom F. Appropriateness criteria for treatment of osteoporotic vertebral compression fractures. Osteoporosis Int. 2018;29:793–804.

[24] Parreira PCS, Maher CG, Megale RZ, et al. An overview of clinical guidelines for the management of vertebral compression fracture: a systematic review. Spine J. 2017;17:1932–8.

[25] Rollinghoff M, Zarghooni K, Schluter-Brust K, et al. Indications and contraindications for vertebroplasty and kyphoplasty. Arch Ortho Trauma Surg. 2010;130:765–74.

[26] Makhni MC, Park PJ, Jimenez J, et al. The medicolegal landscape of spine surgery: how do surgeons fare? Spine J. 2018;18:209–15.

[27] Reschovsky JD, Saiontz-Martinez CB. Malpractice claim fears and the costs of treating medicare patients: a new approach to estimating the costs of defensive medicine. Health Serv Res. 2018;53:1498–516.

[28] Hambali SN, Khodapanahandeh S. A review of medical malpractice issues in Malaysia under tort litigation system. Glob J Health Sci. 2014;6:76–83.

[29] Mukherjee S, Pringle C, Crocker M. A nine-year review of medicolegal claims in neurosurgery. Ann R Coll Surg Engl. 2014;96:266–70.

[30] Tarantino U, Giai Via A, Macri E, et al. Professional liability in orthopaedics and traumatology in Italy. Clin Orthop Relat Res. 2013;471:3349–57.